WANG, TAO
Associate Professorof Pharmacology
Institute of Pharmaceutical Research
Phone: 86-25-83271043
Email: wangtao1331@126.com
Research Summary
Dr. Wang’s research focuses on new drug R&D and mechanism study for type 2 diabetes and metabolic disease. Using various molecular assays, cell-based assays and type 2 diabetic animal models, he has been investigating dozens of substances, obtaining from artificial synthesis, Traditional Chinese Medicine, and marine life. Dr. Wang is also interested in the molecular mechanisms underlining type 2 diabetes, with particular, in mitochondrial plasticity and skeletal muscle glucose metabolismrelated pathway.
Education
2014 Ph.D., Integrated traditional Chinese and Western Medicine, China Pharmaceutical University
2004 M.S., Pharmacology, China Pharmaceutical University
2001 B.S., bio-pharmaceuticals, China Pharmaceutical University
Academic Experience
2015- Associate Professor of Pharmacology, China Pharmaceutical University
2004-2015 Assistant Professor of Pharmacology，China Pharmaceutical University
Awards and Honors
2005 Third Prize, for Natural Science Papers, Nanjing Science and Technology Committee
2013 Second Prize, for Scientific and technological progress, Chinese Ministry of Education
2014 Third Prize, for Scientific and technological progress, Xinjiang Uygur Autonomous Region
Publications
1.Xu ZM, Zhang LY, Li X, Jiang ZZ, Sun LX, Zhao GL, Zhou GH, Zhang H, Shang J*, Wang T*. Mitochondrial fusion/fission process involved in the improvement of catalpol on high glucose-induced hepatic mitochondrial dysfunction. Acta Biochim Biophys Sin (Shanghai). 2015，47(9):730-40.
2. HN Shen，XU Yuan，ZZ Jiang，X Huang，LY Zhang，T Wang*. Inhibitory effects of Tripterygium wilfordii multiglycoside on benign prostatic hyperplasia in rats. Chinese Journal of Natural Medicines. 2015, 13(06):421-427.
3. Wang T, Zhou ZX, Sun LX, Li X, Xu ZM, Chen M, Zhao GL, Jiang ZZ*, Zhang LY*. The protective role of resveratrol against α-naphthylisothiocyanate induced acute cholestasis: involvement of choleretic and anti-inflammatory mechanisms. Acta Pharmacologica Sinica. 2014, 46: 738–748.
4. Li X, Xu ZM, Jiang ZZ, Sun LX, Ji JZ, Miao JS, Zhang XJ, Li XJ, Huang S, Wang T*, Zhang LY*. Hypoglycemic effect of catalpol on high-fat diet/ streptozotocin-induced diabetic mice by increasing skeletal muscle mitochondrial biogenesis. Acta Biochim Biophys Sin. 2014, 46: 738–748.
5. Chen M, Wang T, Jiang ZZ, Shan C, Wang H, Wu MJ, Zhang S, Zhang Y, Zhang LY*. Anti-inflammatory and hepatoprotective effects of total flavonoid C-glycosides from Abrus mollisextracts. Chin J Nat Med. 2014, 12(8):590-598.
6. Shi D*, Guo S, Jiang B, Guo C, Wang T, Zhang L, Li J. HPN, a synthetic analogue of bromophenol from red alga Rhodomela confervoides: synthesis and anti-diabetic effects in C57BL/KsJ-db/db mice. Mar Drugs. 2013, 11(2)：:350-62.
7. Jiang Z, Bao Q, Sun L*, Huang X, Wang T, Zhang S, Li H, Zhang L*. Possible role of mtDNA depletion and respiratory chain defects in aristolochic acid I-induced acute nephrotoxicity. Toxicol Appl Pharmacol. 2013, 266:198-203.
8. Wang J, Jiang Z, Ji J, Li Y, Chen M, Wang Y, Zhang Y, Tai T, Wang T*, Zhang L*. Evaluation of hepatotoxicity and cholestasis in rats treated with EtOH extract of Fructus Psoraleae. Journal of Ethnopharmacology. 2012, 144（1）:73-81
9. Shi D * , Li J, Jiang B, Guo S, Su H, Wang T. Bromophenols as inhibitors of protein tyrosine phosphatase 1B with antidiabetic properties Bioorganic & Medicinal Chemistry Letters. 2012, 22：2827–2832.
10. Fu Q, Huang X, Shu B, Xue M, Zhang P, Wang T, Liu L, Jiang Z, Zhang L*. Inhibition of mitochondrialrespiratory chain is involved in triptolide-induced liver injury. Fitoterapia. 2011, 82(8):1241-8.
11. Zhou Z, Wang T, Jiang Z, Shang J, Liu L , Zhang Y, Zhu D , Huang X, Zhang S, Hu Y, Wang J, Zhang L*. Beneficial effects of colchicine on 17β–ethynylestradiol induced cholestasis in rats. Arzneimittel-Forschung 2011, 61（3）：173-179
12. Wu X, Zhang L, Gurley E, Studer E, Shang J, Wang T, Wang C, Yan M, Jiang Z, Hylemon PB, Sanyal AJ, Pandak WM Jr, Zhou H. Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology. 2008，47(6):1905-15
